Rare cancers in Japan: definition, clinical features and future perspectives.

clinical features incidence network rare cancer rare cancer center

Journal

Japanese journal of clinical oncology
ISSN: 1465-3621
Titre abrégé: Jpn J Clin Oncol
Pays: England
ID NLM: 0313225

Informations de publication

Date de publication:
05 Sep 2020
Historique:
received: 21 05 2020
accepted: 10 07 2020
pubmed: 29 7 2020
medline: 7 10 2020
entrez: 29 7 2020
Statut: ppublish

Résumé

This review introduces the definition, epidemiology and therapeutic challenges of rare cancers and describes the establishment of the Rare Cancer Center at the National Cancer Center, Japan. Rare cancers are defined as malignant tumors with an incidence rate of less than 6 cases per 100 000 individuals. Due to their low incidence rate, medical treatment for rare cancers is more challenging than for more common cancer types. Specifically, 190 types of cancers, including bone and soft tissue sarcomas, gastrointestinal stromal tumors (GISTs), neuroendocrine tumors and gliomas, are classified as rare cancers. Individually, each of the rare cancers accounts for less than 1% of all cancers, but collectively they account for 15% of all cancers. On the basis of their medical management, rare cancers can be subclassified into two types: Type I (rare cancers within cancer-rare organs) and Type II (rare cancers within cancer-common organs). Most importantly, the outcomes for rare cancers are poorer compared to those of common cancers. In 2014, the Rare Cancer Center was established at the National Cancer Center to address the various challenges related to rare cancers. The Rare Cancer Center has adopted a multifaceted approach for overcoming these challenges, including active sharing of information through a dedicated website and an online seminar series 'Rare Cancer Meet the Expert', providing medical support through telephone consultations via a 'Rare Cancer Hotline', supporting basic research and establishing the 'MASTER KEY Project' aimed at developing new treatments.

Identifiants

pubmed: 32719865
pii: 5876940
doi: 10.1093/jjco/hyaa121
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

970-975

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Akira Kawai (A)

Department of Musculoskeletal Oncology and Rehabilitation Medicine, National Cancer Center Hospital, Tokyo, Japan.
Rare Cancer Center, National Cancer Center, Tokyo.

Takahiro Higashi (T)

Rare Cancer Center, National Cancer Center, Tokyo.
Division of Health Services Research, National Cancer Center, Tokyo.

Taro Shibata (T)

Rare Cancer Center, National Cancer Center, Tokyo.
Division of Health Services Research, National Cancer Center, Tokyo.

Akihiko Yoshida (A)

Rare Cancer Center, National Cancer Center, Tokyo.
Department of Pathology, National Cancer Center Hospital, Tokyo.

Yoko Katoh (Y)

Rare Cancer Center, National Cancer Center, Tokyo.

Yasuhiro Fujiwara (Y)

Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo.
Pharmaceuticals and Medical Devices Agency, Tokyo.

Toshirou Nishida (T)

Department of Surgery, National Cancer Center Hospital, Tokyo.
Japan Community Health Care Organization Osaka Hospital, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH